Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

556.55INR
26 Jun 2019
Change (% chg)

Rs6.50 (+1.18%)
Prev Close
Rs550.05
Open
Rs550.00
Day's High
Rs558.80
Day's Low
Rs548.00
Volume
1,020,879
Avg. Vol
2,254,863
52-wk High
Rs678.45
52-wk Low
Rs483.75

Latest Key Developments (Source: Significant Developments)

Cipla To Buy 26% Stake In AMPSolar Power Systems For Up To 129 Mln Rupees
Thursday, 23 May 2019 

May 23 (Reuters) - Cipla Ltd ::SIGNED AGREEMENT TO ACQUIRE 26% STAKE ON A FULLY DILUTED BASIS IN AMPSOLAR POWER SYSTEMS PRIVATE LIMITED.DEAL FOR UP TO 129 MILLION RUPEES.  Full Article

India's Cipla March Qtr Consol Net Profit Falls
Wednesday, 22 May 2019 

May 22 (Reuters) - Cipla Ltd ::MARCH QUARTER CONSOL NET PROFIT 3.67 BILLION RUPEES VERSUS 1.79 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL NET PROFIT WAS 30.89 BILLION RUPEES.MARCH QUARTER CONSOL NET SALES 42.71 BILLION RUPEES VERSUS 34.96 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 3 RUPEES PER SHARE.  Full Article

Cipla Gets Final ANDA Approval For Ambrisentan Tablets From USFDA
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Cipla Ltd ::CIPLA SAYS GOT FINAL ANDA APPROVAL FOR AMBRISENTAN TABLETS 5MG & 10MG FROM USFDA.  Full Article

Cipla Gets EIR From USFDA For Goa Plant
Thursday, 4 Apr 2019 

April 4 (Reuters) - Cipla Ltd ::GETS ESTABLISHMENT INSPECTION REPORT FROM USFDA FOR GOA PLANT.  Full Article

India's Cipla Says Co On Track For 20 Plus Filings In FY19 In North America
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Cipla Ltd ::PLAN TO DRIVE YOY GROWTH FROM COMING QUARTERS ON TRACK.SAYS TRACKING WELL ON GUIDANCE ON LIMITED COMPETITION LAUNCHES AND ANDA APPROVALS.CHALLENGES IN THIS QUARTER WERE ALONG EXPECTED LINES AND CO REMAINS OPTIMISTIC AS IT ENTERS FY'20.SAYS ON TRACK FOR 20+ FILINGS IN FY19 IN NORTH AMERICA.  Full Article

Bio-Thera Solutions Partners With Cipla Ltd To Market Key Cancer Biosimilar
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Cipla Ltd ::BIO-THERA SOLUTIONS LTD PARTNERS WITH CIPLA LTD TO MARKET KEY CANCER BIOSIMILAR.BIO-THERA SOLUTIONS SAYS REACHED A LICENSING AGREEMENT WITH CIPLA FOR BAT1706.BIO-THERA SOLUTIONS SAYS CIPLA WILL HAVE EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET DRUG IN SELECT EMERGING MARKETS.BIO-THERA SOLUTIONS SAYS INTENDS TO FILE FOR REGULATORY APPROVAL FOR BAT-1706 WITH UNITED STATES FOOD AND DRUG ADMINISTRATION (USFDA) IN 2020.  Full Article

Cipla Says Sanctions To Impact Reported Performance In Parts Of Business For Next Two Qtrs
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Cipla Ltd ::SANCTIONS TO IMPACT REPORTED PERFORMANCE IN CERTAIN PARTS OF THE BUSINESS FOR NEXT TWO QTRS.CURRENTLY ENGAGED IN CAPACITY BALANCING IN CERTAIN SPECIFIC CATEGORIES AT PLANTS WHICH WILL HAVE A SHORT-TERM IMPACT.  Full Article

India's Cipla Sept-Qtr Net Profit Down About 11 Pct
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Cipla Ltd ::CONSENSUS FORECAST FOR SEPT QUARTER CONSOL NET PROFIT WAS 4.56 BILLION RUPEES.SEPT QUARTER CONSOL NET SALES 39.48 BILLION RUPEES VERSUS 39.88 BILLION RUPEES LAST YEAR.SEPT QUARTER CONSOL NET PROFIT 3.78 BILLION RUPEES VERSUS 4.23 BILLION RUPEES LAST YEAR.  Full Article

Cipla, Unitaid Announce Deal To Lower Price Of Combination Therapy To Treat Opportunistic Infections In HIV Patients
Friday, 8 Jun 2018 

June 8 (Reuters) - Cipla Ltd ::CIPLA LTD - UNITAID, CO STRUCK DEAL TO LOWER PRICE OF FIRST COMBINATION THERAPY THAT PREVENTS OPPORTUNISTIC INFECTIONS IN PEOPLE LIVING WITH HIV.CIPLA - PRICE OF PRODUCT EXPECTED TO COME DOWN MORE AS GOVTS, INTERNATIONAL FUNDING BODIES PROCURE LARGER QUANTITIES FOR HIV TREATMENT PROGRAMMES.CIPLA - COMBINATION THERAPY CONTAINS CO-TRIMOXAZOLE, ISONIAZID AND VITAMIN B6.CIPLA - CO TO REDUCE CEILING PRICE OF MEDICINE BY MORE THAN 30 PERCENT TO $ 1.99/PERSON/MONTH, FOR PUBLIC-SECTOR PROCURERS IN LOW,MIDDLE-INCOME COUNTRIES.  Full Article

Cipla Says U.S. FDA Conducted Product Specific Pre-Approval Inspection At Goa Plant In Jan
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Cipla Ltd ::CLARIFIES ON NEWS ITEM REGARDING U.S. FDA OBSERVATIONS FOR CO'S GOA UNIT.SAYS RECEIVED CERTAIN OBSERVATIONS WHICH ARE PROCEDURAL IN NATURE.SAYS FDA CONDUCTED PRODUCT SPECIFIC PRE-APPROVAL INSPECTION AT GOA PLANT IN JANUARY 2018.SAYS ‍"AT THIS STAGE, WE DO NOT FORESEE ANY IMPACT ON OTHER PRODUCTS BEING MANUFACTURED/FILED FROM PLANT​".  Full Article

BUZZ-India's Cipla rises after U.S. FDA closes inspection at Goa unit

** Shares of generic drugmaker Cipla Ltd rise as much as 3.41 pct to 538.75 rupees, their highest in a fortnight